Neurogene stock price target maintained at $45 by H.C. Wainwright
PositiveFinancial Markets

H.C. Wainwright has maintained its stock price target for Neurogene at $45, signaling confidence in the company's future performance. This decision reflects the firm's belief in Neurogene's potential growth and stability in the biotech sector, which is crucial for investors looking for reliable opportunities in the market.
— Curated by the World Pulse Now AI Editorial System